<DOC>
	<DOCNO>NCT00490659</DOCNO>
	<brief_summary>The purpose study test feasibility , toxicity efficacy two different adjuvant treatment schedule Stage II-IIIa Non-small cell lung cancer patient positive lymph node .</brief_summary>
	<brief_title>Trial Perioperative Chemotherapy ( Gemcitabine Cisplatin ) Adjuvant Chemoradiotherapy ( With Weekly Low Dose Gemcitabine ) Patients With Lung Cancer With Positive Nodes</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis NSCLC ( subtype ) . For patient enter Arm B also allow confirm histopathological diagnosis NSCLC intraoperatively trial . Node positive ( clinically pathologically ) stage II disease Stage IIIA : T1N1 T2N1 T1N2 T2N2 T3N1 T3 N2 , accord revision Mountain CF American Joint Committee Cancer ( Mountain CF 1997 , Fleming ID et al . 1997 ) . For patient enter Arm B ( N0 stage ) confirmation N1N2 stage must obtain intraoperative postsurgery pathology report . Tumor amenable curative surgical resection . Patients clinically measurable lesion enrol study . Measurability determine accord RECIST criterion . • Pathological evaluation perform mediastinoscopy surgery No prior tumor therapy ( surgery , radiotherapy , chemotherapy , immunotherapy , molecular target therapy , type tumor therapy ) . Treatment within last 30 day investigational drug . Concurrent administration tumor therapy , include radiotherapy , cytotoxic chemotherapy , immunotherapy , molecular target therapy . Serious concomitant disorder ( example , heart failure , poorly control diabetes ) investigator ’ discretion . Presence uncontrolled , active infection require therapy ( discretion investigator. ) . Stage IIIb IV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>